Genetic Testing in Prostate Cancer.

ABSTRACT:

Purpose of review

This review summarizes recent advances in prostate cancer (PCa) genetics.

Recent findings

Upwards of 20% of metastatic castration-resistant prostate tumors (mCRPC) carry homologous recombination (HR) repair gene mutations, of which ~ 10% are germline (inherited). Another ~ 5% exhibit microsatellite instability (MSI-H) and/or mismatch repair deficiency (MMRd). Pembrolizumab is approved for tumors with MMRd, thus patients with mCRPC and MMRd are candidates for pembrolizumab. Emerging data indicate that platinum chemotherapy and poly ADP-ribose polymerase inhibitors (PARPi) are effective in PCa exhibiting HR deficiency. NCCN guidelines now recommend germline and somatic tumor testing in specific clinical scenarios due to treatment and family implications. Gene

SUBMITTER: Sokolova AO 

PROVIDER: S-EPMC10832578 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature